You are here

Pivotal Phase III Data Published on Lemtrada (Alemtuzumab) in Multiple Sclerosis

Drug was more effective than Rebif in reducing relapse rates (Nov. 1)

Results from the CARE-MS I and CARE-MS II pivotal studies of Lemtrada (alemtuzumab, Sanofi/Genzyme) in patients with relapsing-remitting multiple sclerosis (MS) have been published in the November 1 online issue of The Lancet.

In both trials, Lemtrada was significantly more effective at reducing annualized relapse rates than was the active comparator, Rebif (high-dose subcutaneous interferon beta-1a, EMD Serono/Pfizer), and more patients treated with Lemtrada were relapse-free at 2 years. In addition, in CARE-MS II, the accumulation of disability was significantly slowed in patients given Lemtrada versus those given Rebif. Further, patients treated with Lemtrada were significantly more likely to experience improvement in disability scores than were those treated with Rebif, suggesting a reversal of disability in some patients.

CARE-MS I and CARE-MS II (Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis) are randomized phase III studies comparing the investigational treatment alemtuzumab with a standard-of-care MS treatment, Rebif, in patients with relapsing-remitting MS who were naïve to prior treatment or who had relapsed while on prior therapy, respectively.

In both studies, Lemtrada was significantly superior to Rebif in reducing relapses. In CARE-MS I, 78% of patients treated with Lemtrada remained relapse-free for 2 years, compared with 59% of the Rebif group (P P

Data from the CARES II study also showed that Lemtrada reduced the risk of sustained accumulation of disability by 42% compared with Rebif (P = 0.008). The mean disability score for patients treated with Lemtrada decreased over a 2-year period, indicating an improvement in their physical disability, while the mean score for patients given Rebif increased, indicating a worsening of disability (P

Source: Sanofi, October 31, 2012.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs